SCHEMBL4428129

SCHEMBL4428129

c1cc(N2CCC3(CC2)CCN(C2CCC2)CC3)ncc1N1CCC(N2CCOCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL3 Q96JM7 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
HSD11B1 P28845 1/20 0.42
HRH3 Q9Y5N1 4/20 0.41
CDK2 P24941 3/20 0.41
CDK4 P11802 2/20 0.41
CCND1 P24385 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139795 0.95 ALDH1A1 (0.51) SMN1; SMN2KDM4EMEN1ALDH1A1LMNA
SCHEMBL4136714 0.91 L3MBTL3 (0.51) L3MBTL3L3MBTL1HRH3CDK4ADRA1A
SCHEMBL4289427 0.90 L3MBTL3 (0.50) L3MBTL3L3MBTL1HRH3CDK4MBTD1
SCHEMBL4130945 0.88 HRH3 (0.43) SMN1; SMN2KDM4EMEN1ALDH1A1LMNA
SCHEMBL4938014 0.87 HRH3 (0.42) SMN1; SMN2KDM4EMEN1ALDH1A1LMNA
SCHEMBL4147059 0.87 HRH3 (0.45) HSD11B1HRH3CDK4
SCHEMBL4286340 0.86 MAPT (0.42) MAPTL3MBTL3L3MBTL1HRH3ADRA1A
SCHEMBL4137300 0.86 HRH3 (0.53) MEN1ALDH1A1GAAKMT2AL3MBTL3
SCHEMBL4131366 0.86 MAPT (0.43) SMN1; SMN2KDM4EMEN1ALDH1A1LMNA
SCHEMBL4938890 0.85 HRH3 (0.47) SMN1; SMN2KDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 SMN1; SMN2 838/4885KDM4E 1025/4885MEN1 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.